Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

(2020) William J. Sandborn et al.   GASTROENTEROLOGY

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

(2019) Ben Klünder et al.   CLINICAL PHARMACOKINETICS

Exposure‐Response Analyses of Upadacitinib Efficacy in Phase 2 Trials in Rheumatoid Arthritis and Basis for Phase 3 Dose Selection

(2019) Mohamed‐Eslam F. Mohamed et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

(2019) Ahmed Nader et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

(2019) Mohamed‐Eslam F. Mohamed et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

(2019) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

(2019) Ahmed Nader et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication

(2019) Mohamed-Eslam F. Mohamed et al.   CLINICAL PHARMACOKINETICS

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

(2017) Patrick M. Brunner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

JAK inhibitors in dermatology: The promise of a new drug class

(2017) William Damsky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

(2016) Mohamed-Eslam F. Mohamed et al.   CLINICAL PHARMACOKINETICS

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

(2015) Lauren L. Levy et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches

(2014) Donald Y.M. Leung et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-31 Expression by Inflammatory Cells is Preferentially Elevated in Atopic Dermatitis

(2012) GFL Hofbauer et al.   ACTA DERMATO-VENEREOLOGICA

Harnessing dendritic cells in inflammatory skin diseases

(2011) Chung-Ching Chu et al.   SEMINARS IN IMMUNOLOGY

The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients

(2010) Soo-Jin Chung et al.   YONSEI MEDICAL JOURNAL

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS